A potential cancer treatment is progressing. The post Which ASX biotech's shares have jumped more than 10% on positive clinical trial news? appeared first on The Motley Fool Australia.

Abeona's Zevaskyn provides a runway to potential profitability at the price of $3.1 million per treatment. Read my analysis ...

Kraig Biocraft Laboratories (OTCQB:KBLB) deployed one million genetically engineered silkworm eggs across multiple ...

When Gossamer Bio announced poor results from its flagship blood pressure study in February, the San Diego company’s stock ...

First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded ...

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Shares of Aldeyra Therapeutics nosedived nearly 70 percent on Wednesday after the U.S. Food and Drug Administration declined to approve the Lexington company’s experimental eye-drop reproxalap. The ...

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and ...

The Motley Fool reports that in 2026, Gen Z and millennials focus on AI stocks and view dividend investing as a side hustle, ...

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR ...

VolitionRx (VNRX) stock jumped 70% in pre-market after achieving 99% pure tumor DNA isolation and detecting 49/49 cancers in a blind study.